India, Oct. 16 -- 2026 has been a breakout year for Vaxcyte Inc. (PCVX), with a string of positive pipeline developments lending its shares fresh momentum.
The clinical-stage vaccine innovator aims to prevent bacterial infections, with its pipeline targeting diseases such as invasive pneumococcal disease, Group A streptococcal disease and Shigella infections.
The company's lead investigational product is VAX-31, a 31-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia. VAX-24, a 24-valent candidate, is also being developed to prevent IPD, while VAX-XL is an earlier-stage candidate designed to expand pneumococcal serotype coverage. Beyond pneumococcal disease, the compa...